KEYNOTE-B96 final analysis: Merck’s Keytruda cuts death risk by 18% in recurrent ovarian cancer across all-comer population

Merck (NYSE: MRK) has reported final overall survival data from its Phase 3 KEYNOTE-B96 trial showing that Keytruda (pembrolizumab) combined with paclitaxel, with or without bevacizumab, reduced the risk of death by 18% versus chemotherapy alone in patients with platinum-resistant recurrent ovarian cancer regardless of PD-L1 status. The result, presented at the European Society of Gynaecological Oncology 2026 Congress, arrives alongside a positive European Medicines Agency committee opinion recommending approval, and follows an FDA approval granted earlier this year, positioning pembrolizumab as the first PD-1 inhibitor to demonstrate a statistically significant overall survival benefit in this indication across the full patient population.

How does Keytruda’s overall survival data in platinum-resistant ovarian cancer change the competitive treatment landscape for gynecologic oncology in 2026?

The clinical significance of the KEYNOTE-B96 final analysis lies less in the headline hazard ratio and more in what the data accomplishes structurally. Platinum-resistant recurrent ovarian cancer has been one of oncology’s more stubborn problems: patients who relapse within six months of platinum-based therapy respond poorly to most subsequent regimens, and median overall survival in this setting has historically hovered in the 12-to-14 month range. A median overall survival of 17.7 months in the pembrolizumab arm versus 14.0 months in the control arm represents a meaningful shift against that historical backdrop, even if the absolute gain of 3.7 months will be weighed carefully by payers and prescribers against the added toxicity burden.

The “all comers” framing is strategically important. The original primary endpoint analysis presented at the European Society for Medical Oncology 2025 Congress confirmed progression-free survival benefit across the full population and overall survival benefit in PD-L1-positive patients (Combined Positive Score of at least 1). The final analysis now confirms that the overall survival improvement extends to patients regardless of PD-L1 expression, which removes a companion diagnostic gating requirement from the commercial equation in markets where the label reflects all-comer data. For Merck’s commercial team, that distinction matters: biomarker-unrestricted indications reduce access friction and broaden the addressable prescribing population.

What does the dual FDA approval and CHMP positive opinion signal about regulatory momentum for pembrolizumab in gynecologic cancers?

The near-simultaneous FDA approval and European Medicines Agency Committee for Medicinal Products for Human Use positive opinion create a coordinated global commercial launch window that Merck has clearly been engineering. The FDA approval is scoped to PD-L1-positive patients (Combined Positive Score of at least 1), while the CHMP opinion mirrors that restriction. The all-comer survival benefit, now confirmed at final analysis, may provide a basis for label expansion discussions, though that pathway is not guaranteed and would require separate regulatory engagement.

For institutional investors tracking Merck’s pipeline execution, the dual regulatory outcome matters in the context of the company’s longer-term strategic challenge: the looming loss of exclusivity for pembrolizumab itself, which represents a dominant share of Merck’s revenue base. Each new indication Merck secures for pembrolizumab before biosimilar entry both extends the therapy’s commercial utility and creates a body of clinical evidence that may confer some practical stickiness with oncologists accustomed to the drug’s safety profile. Ovarian cancer is not a blockbuster indication by volume, but it is strategically meaningful as part of a broader effort to demonstrate that pembrolizumab remains the default PD-1 backbone across tumor types.

What are the execution risks and competitive pressures Merck faces in converting KEYNOTE-B96 data into durable commercial performance?

Merck is not operating in a vacuum. The gynecologic oncology space has seen significant investment from competitors pursuing antibody-drug conjugates, PARP inhibitors in earlier lines, and novel combinations. Mirvetuximab soravtansine, approved for folate receptor alpha-positive platinum-resistant ovarian cancer, has established a differentiated biomarker-selected niche. Antibody-drug conjugates more broadly are generating competitive pressure across multiple solid tumor types, and several are in active development for ovarian indications. Merck’s pembrolizumab-based regimen competes on the strength of an established safety database and now a confirmed overall survival signal, but oncologists will weigh those advantages against sequencing considerations, prior bevacizumab exposure, and the added immune-mediated adverse event burden.

The safety data from KEYNOTE-B96 deserve scrutiny on that last point. Grade 3 or higher treatment-related adverse events occurred in 67.8% of patients in the pembrolizumab arm versus 55.3% in the placebo arm, a meaningful differential. Immune-mediated adverse events of any grade were reported in 39.4% of patients receiving pembrolizumab, with hypothyroidism occurring in 18.1%. While no new safety signals emerged and treatment-related mortality rates were comparable between arms, the elevated toxicity profile in a population already managing recurrent disease will factor into physician and patient decision-making, particularly in community oncology settings where immune-mediated event management resources vary.

The bevacizumab optionality embedded in the trial design adds another layer of commercial complexity. Bevacizumab eligibility is determined by investigator judgment prior to randomization, meaning real-world prescribing patterns may diverge substantially from trial enrollment. Patients ineligible for bevacizumab represent a subset of the addressable population, and the contribution of bevacizumab to the combination’s efficacy is not cleanly isolated by the trial design, which could complicate formulary and reimbursement negotiations in systems that scrutinize multi-agent regimens.

How does this trial result reflect the broader maturation of PD-1 inhibitor combinations in difficult-to-treat solid tumors?

KEYNOTE-B96 illustrates a pattern that has become familiar in oncology: PD-1 inhibitor combinations that fail to move the needle on overall survival in initial or interim analyses ultimately demonstrating a benefit at final analysis after longer follow-up. The 32.7-month median follow-up reported here gave the survival curves sufficient time to separate in a way that crossed the statistical threshold. This is not a criticism of the trial design but a reminder that overall survival endpoints in recurrent solid tumors require patience, and that interim progression-free survival data, while clinically useful, can be an imperfect proxy for the outcome that ultimately governs regulatory and reimbursement decisions in most markets.

For the broader field, the confirmation of overall survival benefit in platinum-resistant ovarian cancer regardless of PD-L1 status adds to a growing body of evidence that PD-1 pathway inhibition has durable clinical utility in gynecologic cancers, even where the signal is more modest than in highly immunogenic tumor types like melanoma or certain lung cancers. The data will likely influence ongoing and planned trials in adjacent settings, including earlier lines of ovarian cancer therapy and combination strategies with novel agents.

Key takeaways: What the KEYNOTE-B96 final analysis means for Merck, its competitors, and the gynecologic oncology market

• The confirmed overall survival benefit in all-comer platinum-resistant ovarian cancer patients, regardless of PD-L1 status, removes a key commercial barrier and broadens Merck’s addressable prescribing population beyond what the current PD-L1-restricted label allows in the US and Europe.
• Median overall survival of 17.7 months versus 14.0 months represents one of the longest reported in any clinical trial for this indication, providing Merck with a differentiated efficacy narrative in a historically difficult setting.
• Dual regulatory progress, FDA approval and a CHMP positive opinion, creates a synchronized global launch window that maximizes near-term commercial impact ahead of the more complex patent cliff dynamics Merck faces with pembrolizumab.
• The elevated Grade 3-plus adverse event rate of 67.8% in the pembrolizumab arm versus 55.3% for chemotherapy alone will be a meaningful friction point in community oncology settings and payer formulary reviews.
• Bevacizumab eligibility as an investigator-determined variable introduces real-world prescribing complexity that may cause actual utilization patterns to diverge from the trial’s enrollment mix.
• Antibody-drug conjugates and biomarker-selected agents like mirvetuximab soravtansine remain competitive alternatives in platinum-resistant ovarian cancer, and their continued development will shape sequencing decisions.
• Each new pembrolizumab indication secured before biosimilar entry contributes incrementally to the drug’s embedded clinical utility and prescriber familiarity, which may provide some commercial resilience in a post-exclusivity environment.
• The all-comer survival result may support future label expansion discussions in the EU and US, though that pathway requires separate regulatory submissions and is not guaranteed.
• The trial’s extended 32.7-month median follow-up underscores the importance of patience in solid tumor overall survival endpoint design, a methodological consideration relevant to ongoing trials across the PD-1 inhibitor field.
• Merck’s continued investment in women’s oncology through both KEYNOTE-B96 and its broader gynecologic pipeline signals a deliberate effort to build indication depth in a therapeutic area where unmet need remains high and competitive dynamics are still evolving.